Among the chief discrepancies between the House and Senate health reform proposals is a provision of the House bill that would allow states to negotiate directly with pharmaceutical companies for lower drug prices on behalf of their lowest income seniors — those eligible for both Medicare and Medicaid. House leaders, More…
While we’re on the topic of that $80 billion deal struck between Democratic leaders and the nation’s drug makers, it’s worth clarifying how it came to be. Many in the press have reported that the deal originated in the White House, which is perfectly understandable because More…
On Monday, The New York Times ran a damning story detailing how the nation’s drug makers are hiking their prices ahead of the reform laws winding their way through Congress. The very next day, some powerful House Democrats called for a closer look, asking the Government Accountability Office More…
The Washington Post’s Ezra Klein hits the nail on the head today regarding the toughest hurdle Democrats face in passing health reform this year: Namely, the inertial force of the medical-industrial complex that’s been built up around the inefficient health system that’s in place.
The central problem in
rss